Mergers & acquisitions
Valeritas and its subsidiaries filed for Chapter 11 bankruptcy on February 9, 2020 in the District of Delaware. At the same time, Zealand entered into the definitive deal to buy the assets.
Three months after Sandoz announced it would acquire the Japanese business of Aspen Global Incorporated, a subsidiary of Aspen Pharmacare Holdings for $330 million, the deal has been completed.
The merged companies will operate under the name Histogen and trade on the Nasdaq Capital Market under a new ticker symbol.
The company announced it had rejected the bid, saying that it “significantly undervalues Sorrento and is not in the best interest of the Company’s stockholders.”
As AbbVie and Allergan near completion of the $63 billion merger, the two companies are shedding some assets in order to meet demands of regulators over concerns of a monopoly.
Nuvisan Pharma Services announces its acquisition of Inamed GmbH, an international CRO specialized in clinical trials with patients living with respiratory and rare diseases.
Recipharm announces that it has this morning acquired 4,881,437 Consort Shares, representing 9.9 per cent. of the existing issued share capital of Consort Medical, at 1,010 pence per share and a further 118,563 Consort Shares, representing 0.2 per cent. of the existing issued share capital of Consort Medical at 1,000 pence per share.
First drug product facility in Europe to complement WuXi Biologics’ existing commercial manufacturing capacities
“This acquisition fits with our strategy to expand our capabilities and build our presence in the U.S. and further strengthens our immunotherapy pipeline,” said Ugur Sahin, co-founder and chief executive officer of BioNTech.
DLA Piper is pleased to announce that the firm represented Osceola Capital, a middle-market private equity firm focused on services businesses, in its acquisition of Healthcents, Inc., a leading provider of medical reimbursement and related services.
PRESS RELEASES